Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria

Journal of Controlled Release(2024)10.1016/j.jconrel.2024.04.052Source: DataRank Database

Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria is a research paper published in Journal of Controlled Release (2024). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 6.62)OA: hybridTopics (83)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Ilke Aernout ORCID,Joke Deprez ORCID,Yanou Engelen ORCID,Margo De Velder,Lorenzo Franceschini ORCID

Live enrichment

PubMed:38697317 OpenAlex:https://openalex.org/W4396633335

European Commission

Grant: 101080544

Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines

FWO

Kom op tegen kanker

Horizon Europe

FWCI

6.62

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://ars.els-cdn.com/content/image/1-s2.0-S0168365924002815-ga1_lrg.jpg

publisherhttps://ars.els-cdn.com/content/image/1-s2.0-S0168365924002815-ga1_lrg.jpg

publisherhttps://api.elsevier.com/content/article/PII:S0168365924002815?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0168365924002815?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jconrel.2024.04.052

Fields of Study

Immune Cell Function and InteractionRNA Interference and Gene DeliveryImmunotherapy and Immune Responses0301 basic medicine03 medical and health sciences0303 health sciencesAnimalsGalactosylceramidesMice, Inbred C57BLCancer VaccinesFemaleNanoparticlesOvalbuminmRNA VaccinesAdjuvants, ImmunologicCD8-Positive T-LymphocytesRNA, MessengerMiceBacterial VaccinesNeoplasmsLipidsLiposomes

MeSH Terms

mRNA VaccinesAdjuvants, ImmunologicAnimalsBacterial VaccinesFemaleGalactosylceramidesLipidsLiposomesMice, Inbred C57BLNeoplasmsOvalbuminRNA, MessengerCD8-Positive T-LymphocytesCancer VaccinesMiceNanoparticles

Keywords

AdjuvantImmunogenicityImmune systemMessenger RNABiologyChemistryImmunologyBiochemistryCancerIntracellular bacteriaNKT cellLipoplexLipid NanoparticleRoute Of AdministrationΑ-galactosylceramideModified NucleotidesMrna VaccineOvalbuminGalactosylceramidesINNATECD8-Positive T-LymphocytesDENDRITIC CELLSCancer VaccinesDELIVERYMiceAdjuvants, ImmunologicCLASS-INeoplasmsSUPPRESSOR-CELLSAnimalsRNA, MessengerLISTERIA-MONOCYTOGENESKILLER T-CELLSNKT CELLSIMMUNE-RESPONSESbacterial infectionBiology and Life SciencesLipidsMice, Inbred C57BLBacterial VaccinesLiposomesalpha-GalactosylceramideNanoparticlesFemalemRNA Vaccines

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being